Immunity to SARS-CoV-2 after vaccination and previous infection: COVID - 19 immunity study, Namibia

Résumé

Abstract Background: Severe Acute Respiratory Syndrome Coronavirus Disease 2019 (COVID - 19) caused by SARS-CoV-2 virus has had a devastating global impact, leading to millions of deaths. The rollout of COVID - 19 vaccines has been critical in controlling the pandemic. In Namibia, the COVID - 19 vaccine rollout began in March 2021, with a national target of vaccinating at least 60% of the population. This study aimed to evaluate the immune response to COVID - 19 infection and vaccination with either Sinopharm, Covishield, Pfizer and Jansen vaccines. The study population consisted of participants residing in Oranjemund, Namibia. Methods and Results: We enrolled 260 participants, among which 80.4% had received COVID - 19 vaccination. Serum samples were collected between December 15, 2021, and June 15, 2022. Levels of anti-SARS-CoV-2 spike (anti-S) and anti-SARS-CoV-2 nucleocapsid (anti-N) antibodies in vaccinated and unvaccinated individuals were measured using qualitative and quantitative chemiluminescence immunoassays. The results showed that 92.5%(n=112) participants with laboratory-confirmed COVID - 19 infection had detectable anti-N antibodies, indicating immunity due to prior infection. 54.6% (n=76) of individuals without a history of infection also had reactive anti-N antibodies, suggesting immunity. All vaccinated participants showed the production of anti-S antibodies. 99.5% (n=187) of individuals with anti-N antibodies had detectable anti-S antibodies. Notably, 7.5% (n=9) of participants with a history of COVID - 19 infection did not have detectable anti-N antibodies. We found a strong correlation r2 = 0.69 (p-value = 3.755e-11) between COVID - 19 diagnosis and testing positive (reactive) for Anti-N antibodies. Conclusions: We found a high level of detectable anti-N antibodies in patients who had a history of COVID - 19 infection and anti-S antibodies in those who were vaccinated. The study provides insights into the immune response to COVID - 19 infection and vaccination in Namibia, contributing to the understanding of vaccine effectiveness and development of immunity.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0